Market Overview

Organovo Continues To Gain On Positive 3D Tissue Results

Related ONVO
Add 3D Printing To Your Portfolio With These Stocks
Organovo Holdings Sees FY 2016 Revs From Prior Bookings Of $1.2M-$1.4M
Organovo Holdings' (ONVO) CEO Keith Murphy on Q3 2016 Results - Earnings Call Transcript (Seeking Alpha)

Shares of Organovo (NYSE: ONVO) gained another nine percent in Friday's trading following an 11.7 percent gain on Thursday.

Organovo reported positive results from a collaborative study using the company's 3D Human Liver Tissues on Thursday. The news drove shares up more than 12 percent, with the stock closing at $8.20.

Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented at the 3D Cell Conference in Germany on June 25. The results concluded that Organovo's 3D Liver was able to distinguish between a hepatoxic drug from a similar non-toxic chemical analog.

Shares of Organovo closed at $8.60, up 4.88 percent.

Posted-In: Long Ideas News Short Ideas Global Trading Ideas


Related Articles (ONVO)

View Comments and Join the Discussion!

Get Benzinga's Newsletters